Total Funding
57
20
Total FundingDebt Financing raised
Growth Score
-2 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
753166
Vaxent’s lead product in development is a subunit vaccine against group A streptococcus.
- James Dale: Co-Founder and Chief Scientific Officer
About the Company
Vaxent’s lead product in development is a subunit vaccine against group A streptococcus which has been tested in early stage human clinical trials. The company plans to use its core competency in protein vaccine technology to advance its lead product in clinical testing, as well as develop other new vaccines against infectious diseases.
